AJP - GI Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol (February 1, 2007). doi:10.1152/ajpgi.00497.2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/5/G1337    most recent
00497.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guicciardi, M. E.
Right arrow Articles by Gores, G. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guicciardi, M. E.
Right arrow Articles by Gores, G. J
Submitted on October 24, 2006
Accepted on January 30, 2007

c-FLIPL Prevents TRAIL-Induced Apoptosis of Hepatocellular Carcinoma Cells by Inhibiting the Lysosomal Pathway of Apoptosis

Maria Eugenia Guicciardi1, Steven F. Bronk2, Nathan W. Werneburg2, and Gregory J Gores1*

1 Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, United States
2 Rochester, Minnesota, United States; Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, United States

* To whom correspondence should be addressed. E-mail: gores.gregory{at}mayo.edu.

Sensitivity to TRAIL-mediated apoptosis and the lysosomal pathway of cell death are features of cancer cells. However, it is unknown if TRAIL cytotoxic signaling engages the lysosomal pathway of cell death. Our aim, therefore, was to ascertain if TRAIL killing involves lysosomal permeabilization. TRAIL-induced apoptosis of hepatocellular carcinoma cells (HuH-7, Hep3B) was associated with lysosomal permeabilization as demonstrated by redistribution of the lysosomal protease cathepsin B into the cytosol. Pharmacological and shRNA-targeted inhibition of cathepsin B reduced apoptosis. Because cFLIP inhibits TRAIL-induced cell death and is frequently overexpressed by human cancers, the ability of cFLIP to prevent lysosomal permeabilization during TRAIL treatment was examined. Enforced cFLIPL expression reduced release of cathepsin B from lysosomes and attenuated apoptosis. cFLIPL-overexpression was also associated with robust p42/44 MAPK activation following exposure to TRAIL. In contrast, cFLIPL-overexpression attenuated p38 MAPK activation and had no significant effect on JNK and NF-{kappa}B activation. Inhibition of p42/44 MAPK by PD98059 restored TRAIL-mediated lysosomal permeabilization and apoptosis in cFLIP-overexpressing cells. In conclusion, these results demonstrate that lysosomal permeabilization contributes to TRAIL-induced apoptosis of hepatocellular carcinoma cells, and suggest cFLIPL cytoprotection is, in part, due to p42/44 MAPK-dependent inhibition of lysosomal breakdown.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.